EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 62 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR Olaparib after Initial Treatment Delays Ovarian Cancer Progression November 20, 2018 Pembrolizumab Demonstrates Robust and Durable Antitumour Activity in Patients with Previously... January 13, 2022 Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... February 12, 2020 How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... April 14, 2021 Load more HOT NEWS 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute... At 27, She Was Told She Was Too Young For Breast... Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite...
